Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Free Cash Flow (2024 - 2025)

Xilio Therapeutics' Free Cash Flow history spans 2 years, with the latest figure at -$17.5 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 27.77% year-over-year to -$17.5 million; the TTM value through Sep 2025 reached -$17.6 million, changed N/A, while the annual FY2024 figure was -$18.4 million, 73.35% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$17.5 million at Xilio Therapeutics, down from -$14.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $28.7 million in Q1 2025 and bottomed at -$17.5 million in Q3 2025.